David C. Limburg

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life

Jane L. Wang, David C. Limburg, Matthew J. Graneto et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 324 citations · Full text

Medicinal Chemistry, Novel Benzopyran Class, Favorable Human Half-life +11

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)((1 <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

Andrew Fensome, Catherine M. Ambler, Eric P. Arnold et al. · Journal of Medicinal Chemistry · 2018 · 165 citations · Full text

1-Cyanoimidazole as a Mild and Efficient Electrophilic Cyanating Agent

Yong‐Qian Wu, David C. Limburg, Douglas E. Wilkinson et al. · Organic Letters · 2000 · 94 citations

Heterocyclic, Carbanion Nucleophiles, Organic Electrochemistry +6

Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay

Christoph W. Zapf, Brian S. Gerstenberger, Xing Li et al. · Journal of Medicinal Chemistry · 2012 · 77 citations · Full text

A mild deprotection procedure for tert-butyl esters and tert-butyl ethers using ZnBr2 in methylene chloride

Yong‐Qian Wu, David C. Limburg, Douglas E. Wilkinson et al. · Tetrahedron Letters · 2000 · 64 citations

Chemical Engineering, Tert-butyl Esters, Engineering +4